+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gout Therapeutics Market By Drug Condition, By Disease Condition, and By Distribution Channel: Global Industry Perspective Comprehensive Analysis, and Forecast, 2018-2025

  • ID: 5144052
  • Report
  • October 2019
  • Region: Global
  • 130 pages
  • Zion Market Research
The report covers a forecast and an analysis of the gout therapeutics market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints of the gout therapeutics market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the gout therapeutics market on a global level.

In order to give the users of this report a comprehensive view of the gout therapeutics market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the gout therapeutics market by segmenting it based on drug type, disease condition, distribution channel, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Some key players in the global gout therapeutics market include Teijin Pharma, Takeda Pharmaceutical, Novartis, Mylan, Horizon Pharma, Teva Pharmaceutical, Iroko Pharmaceuticals, Hikma Pharmaceuticals, and Merck.

This report segments the global gout therapeutics market as follows:

Global Gout Therapeutics Market: Drug Type Analysis
  • Colchicine
  • Antihyperuricemic Agents
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Biologics
Global Gout Therapeutics Market: Disease Condition Analysis
  • Acute Gout
  • Chronic Gout
Global Gout Therapeutics Market: Distribution Channel Analysis
  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Sales
Global Gout Therapeutics Market: Regional Analysis
  • North America
  • The U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa
Note: Product cover images may vary from those shown
  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Gout Therapeutics Market, 2016-2025 (USD Million)
    • 2.2. Gout Therapeutics Market: Snapshot
  • Chapter 3. Gout Therapeutics Market - Industry Analysis
    • 3.1. Gout Therapeutics Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. A rise in the prevalence of gout arthritis
      • 3.2.2. Increase in patient preference for biologics
      • 3.2.3. Introduction of urate-lowering agents
    • 3.3. Restraints
      • 3.3.1. Competition from generic drugs
      • 3.3.2. The high cost of biologics
    • 3.4. Opportunity
      • 3.4.1. Promising drug pipeline and approvals
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis by drug type
      • 3.6.2. Market attractiveness analysis by disease condition
      • 3.6.3. Market attractiveness analysis by distribution channel
      • 3.6.4. Market attractiveness analysis by region
  • Chapter 4. Gout Therapeutics Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global gout therapeutics market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New product launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Gout Therapeutics Market - Drug Type Analysis
    • 5.1. Global gout therapeutics market overview: by drug type
      • 5.1.1. Global gout therapeutics market share, by drug type, 2018 and 2025
    • 5.2. Colchicine
      • 5.2.1. Global gout therapeutics market by colchicine, 2016-2025 (USD Million)
    • 5.3. Antihyperuricemic Agents
      • 5.3.1. Global gout therapeutics market by Antihyperuricemic agents, 2016-2025 (USD Million)
    • 5.4. Non-Steroidal Anti-Inflammatory Drugs
      • 5.4.1. Global gout therapeutics market by non-steroidal anti-inflammatory drugs, 2016-2025 (USD Million)
    • 5.5. Corticosteroids
      • 5.5.1. Global gout therapeutics market by corticosteroids, 2016-2025 (USD Million)
    • 5.6. Biologics
      • 5.6.1. Global gout therapeutics market by biologics, 2016-2025 (USD Million)
  • Chapter 6. Global Gout Therapeutics Market -Disease Condition Analysis
    • 6.1. Global gout therapeutics market overview: by disease condition
      • 6.1.1. Global gout therapeutics market share, by disease condition, 2018 and 2025
    • 6.2. Acute Gout
      • 6.2.1. Global gout therapeutics market by acute gout, 2016-2025 (USD Million)
    • 6.3. Chronic Gout
      • 6.3.1. Global gout therapeutics market by chronic gout, 2016-2025 (USD Million)
  • Chapter 7. Global Gout Therapeutics Market - Distribution Channel Analysis
    • 7.1. Global gout therapeutics market overview: by distribution channel
      • 7.1.1. Global gout therapeutics market share, by distribution channel, 2018 and 2025
    • 7.2. Retail Pharmacy
      • 7.2.1. Global gout therapeutics market by retail pharmacy, 2016-2025 (USD Million)
    • 7.3. Hospital Pharmacy
      • 7.3.1. Global gout therapeutics market by hospital pharmacy, 2016-2025 (USD Million)
    • 7.4. Online Sales
      • 7.4.1. Global gout therapeutics market by online sales, 2016-2025 (USD Million)
  • Chapter 8. Global Gout Therapeutics Market - Regional Analysis
    • 8.1. Global gout therapeutics market overview: by region
      • 8.1.1. Global gout therapeutics market share, by region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America gout therapeutics market, 2016-2025 (USD Million)
      • 8.2.2. North America gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
      • 8.2.3. North America gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
      • 8.2.4. North America gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.2.5. The U.S.
        • 8.2.5.1. The U.S. gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
        • 8.2.5.2. The U.S. gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
        • 8.2.5.3. The U.S. gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.2.6. Rest of North America
        • 8.2.6.1. Rest of North America gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
        • 8.2.6.2. Rest of North America gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
        • 8.2.6.3. Rest of North America gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
    • 8.3. Europe
      • 8.3.1. Europe gout therapeutics market, 2016-2025 (USD Million)
      • 8.3.2. Europe gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
      • 8.3.3. Europe gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
      • 8.3.4. Europe gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.3.5. UK
        • 8.3.5.1. U.K. gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
        • 8.3.5.2. U.K. gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
        • 8.3.5.3. U.K. gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.3.6. France
        • 8.3.6.1. France gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
        • 8.3.6.2. France gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
        • 8.3.6.3. France gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.3.7. Germany
        • 8.3.7.1. Germany gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
        • 8.3.7.2. Germany gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
        • 8.3.7.3. Germany gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.3.8. Rest of Europe
        • 8.3.8.1. Rest of Europe gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
        • 8.3.8.2. Rest of Europe gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
        • 8.3.8.3. Rest of Europe gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific gout therapeutics market, 2016-2025 (USD Million)
      • 8.4.2. Asia Pacific gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
      • 8.4.3. Asia Pacific gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
      • 8.4.4. Asia Pacific gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.4.5. China
        • 8.4.5.1. China gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
        • 8.4.5.2. China gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
        • 8.4.5.3. China gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.4.6. Japan
        • 8.4.6.1. Japan gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
        • 8.4.6.2. Japan gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
        • 8.4.6.3. Japan gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.4.7. India
        • 8.4.7.1. India gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
        • 8.4.7.2. India gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
        • 8.4.7.3. India gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
        • 8.4.8.2. Rest of Asia Pacific gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
        • 8.4.8.3. Rest of Asia Pacific gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America gout therapeutics market, 2016-2025 (USD Million)
      • 8.5.2. Latin America gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
      • 8.5.3. Latin America gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
      • 8.5.4. Latin America gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.5.5. Brazil
        • 8.5.5.1. Brazil gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
        • 8.5.5.2. Brazil gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
        • 8.5.5.3. Brazil gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
      • 8.5.6. Rest of Latin America
        • 8.5.6.1. Rest of Latin America gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
        • 8.5.6.2. Rest of Latin America gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
        • 8.5.6.3. Rest of Latin America gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa gout therapeutics market, 2016-2025 (USD Million)
      • 8.6.2. The Middle East and Africa gout therapeutics market revenue, by drug type, 2016-2025 (USD Million)
      • 8.6.3. The Middle East and Africa gout therapeutics market revenue, by disease condition, 2016-2025 (USD Million)
      • 8.6.4. The Middle East and Africa gout therapeutics market revenue, by distribution channel, 2016-2025 (USD Million)
  • Chapter 9. Company Profiles
    • 9.1. Teijin Pharma
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Product Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. Takeda Pharmaceutical
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Product Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. Novartis
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Product Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Developments
    • 9.4. Mylan
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Product Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Developments
    • 9.5. Horizon Pharma
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Product Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Development
    • 9.6. Teva Pharmaceutical
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Product Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Development
    • 9.7. Iroko Pharmaceuticals
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Product Portfolio
      • 9.7.4. Business Strategy
      • 9.7.5. Recent Development
    • 9.8. Hikma Pharmaceuticals
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Product Portfolio
      • 9.8.4. Business Strategy
      • 9.8.5. Recent Development
    • 9.9. Merck
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Product Portfolio
      • 9.9.4. Business Strategy
      • 9.9.5. Recent Development
Note: Product cover images may vary from those shown
Adroll
adroll